Sang Soo Kim

Title: Innovations by Sang Soo Kim in Cancer Immunotherapy

Introduction

Sang Soo Kim is an accomplished inventor based in Rockville, MD, who has made significant contributions to the field of cancer treatment. His innovative work focuses on enhancing the effectiveness of immunotherapy, particularly through the use of gene therapy.

Latest Patents

Sang Soo Kim holds a patent for "Methods for reducing side effects of immunotherapy." This invention addresses the limitations of immune checkpoint immunotherapy by providing more effective methods for treating cancer. The patent outlines a means of utilizing p53 gene therapy to augment immune checkpoint inhibition. This is achieved by combining antibodies that target immune checkpoint molecules with SGT-53, a nanomedicine that carries a plasmid encoding human wild-type p53. The invention aims to increase tumor immunogenicity, enhance both innate and adaptive immune responses, and reduce tumor-induced immunosuppression. Additionally, it sensitizes otherwise refractory tumors to anti-immune checkpoint antibodies while unexpectedly reducing the immune-related toxicities commonly associated with immunotherapies.

Career Highlights

Throughout his career, Sang Soo Kim has worked with notable organizations, including Synergene Therapeutics, Inc. and Georgetown University. His experience in these institutions has allowed him to develop and refine his innovative approaches to cancer treatment.

Collaborations

Sang Soo Kim has collaborated with esteemed colleagues such as Esther H. Chang and Joe B. Harford, contributing to the advancement of research in immunotherapy.

Conclusion

Sang Soo Kim's work in cancer immunotherapy exemplifies the potential of innovative approaches to improve treatment outcomes. His patent on methods for reducing side effects of immunotherapy highlights the importance of combining gene therapy with existing treatments to enhance their effectiveness.